logo
Plus   Neg
Share
Email

Astellas Pharma To Buy Audentes Therapeutics In $3 Bln Deal

Astellas Pharma Inc agreed to acquire Audentes Therapeutics Inc. (BOLD) for US$60.00 per share in cash, representing a total equity value of about US$3 billion.

The offer price represents a premium of 110% to Audentes' closing share price of US$28.61 on December 2, 2019.

Asilomar will commence a tender offer for all outstanding shares of common stock of Audentes. The Tender Offer period is expected to commence in the next few weeks and to expire 20 business days after its commencement, unless otherwise extended.

Astellas said it is still reviewing the impact of a consummation of the transaction on its financial results for the fiscal year ending March 31, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Golden Pearl Trading Corp. is recalling certain ready-to-eat or RTE imported Siluriformes products that were produced without benefit of import inspection, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves around 12,054 pounds of Siluriformes products that were not presented for import re-inspection into the United States. The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft... STIHL recalls about 16,400 STIHL RE 90 pressure washers due to injury hazard. According to the company, the recalled pressure washer nozzle can disconnect from the spray wand when under pressure during use, posing an injury hazard. STIHL said it received seven reports of the nozzle detaching from...
Follow RTT
>